HC Wainwright & Co. Reiterates Buy on NewAmsterdam Pharma Co, Maintains $52 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.7%

Neg 0% Neu 90.7% Pos 0%

HC Wainwright & Co. analyst Lander Egaña Gorroño reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $52 price target.